The pharmaceutical industry is characterized by a completely unpredictable business, in which a stroke of good fortune can tell success from failure. But worse is that the distance between success and failure in one product, it may mean to stop selling one billion euros! Each year! The story of the discovery of Viagra illustrates this so excellent, as is the story of a failure that became a business success unprecedented by a stroke of fate. Erectile dysfunction affects 10 percent of men. But that figure rose to 52 percent in men 40 to 70 years. Viagra is not the only but it was the first oral drug against impotence. Currently sold almost two billion euros per year, with profit margins approaching 90%. The story of the discovery is interesting because it illustrates how a stroke of luck could change the profits of an enterprise. is something that does not happen in any other business with this magnitude, with that sense of fate. Although of course you have to keep ready to identify opportunities.
all began in 1985 when Campbell and David Simon Roberts, both chemists at Pfizer, undertook the task of finding a compound of hypertension, discovering the sildenafil. Pfizer began clinical trials of phase I of sildenafil in healthy volunteers with no history of coronary heart disease, six years later, in July 1991. The following year, two things happened in parallel, changing the direction of research. Upon entering Phase II, the drug did not meet the expectations of the team in terms of activity in patients with severe coronary heart disease. However, during a study in which the dose was increased to the maximum, to see how drugs could be given to volunteers without incurring side effects, the volunteers showed side effects, including headache, indigestion, visual problems, muscle aches, and a change in erectile function. An interesting side effect ... For the team that discovered this change in erectile function was an interesting phenomenon. As the drug did not appear promising to treat patients with coronary disease, the team discussed the possibility of using sildenafil as a therapeutic drug against impotence. In May 1994, Pfizer began the first Phase II trial of sildenafil in men suffering from impotence. The rest is history. A business success story and pharmacist. Indeed, the active substance is white, blue is Marketing. If you have not tried it, is awesome, I assure you, I always I have some on hand just in case ;-).
all began in 1985 when Campbell and David Simon Roberts, both chemists at Pfizer, undertook the task of finding a compound of hypertension, discovering the sildenafil. Pfizer began clinical trials of phase I of sildenafil in healthy volunteers with no history of coronary heart disease, six years later, in July 1991. The following year, two things happened in parallel, changing the direction of research. Upon entering Phase II, the drug did not meet the expectations of the team in terms of activity in patients with severe coronary heart disease. However, during a study in which the dose was increased to the maximum, to see how drugs could be given to volunteers without incurring side effects, the volunteers showed side effects, including headache, indigestion, visual problems, muscle aches, and a change in erectile function. An interesting side effect ... For the team that discovered this change in erectile function was an interesting phenomenon. As the drug did not appear promising to treat patients with coronary disease, the team discussed the possibility of using sildenafil as a therapeutic drug against impotence. In May 1994, Pfizer began the first Phase II trial of sildenafil in men suffering from impotence. The rest is history. A business success story and pharmacist. Indeed, the active substance is white, blue is Marketing. If you have not tried it, is awesome, I assure you, I always I have some on hand just in case ;-).
0 comments:
Post a Comment